學術成果

上海立聞基于以MiniPDX為主的功能性檢測平臺，通過與臨床專家的進行深層次的研究合作；目前已經發表學術論文多篇，其中以SCI為主。

我要咨詢

聯系我們

平臺介紹

上海立聞基于以MiniPDX為主的功能性檢測平臺，通過與臨床專家的進行深層次的研究合作；目前已經發表學術論文多篇，其中以SCI為主.
上海立聞擁有著獨特的轉化醫學平臺，在臨床研究和基礎研究之間提供重要的媒介：一方面，我們基于MiniPDX的臨床檢測服務，可以協助臨床醫生進行以MiniPDX指導臨床用藥的臨床研究的成果轉化；另一方面，我們依托PDX和MiniPDX在內的功能性檢測、多組學檢測、及蛋白組學的綜合性科研服務平臺，可以助力基礎研究的轉化。
臨床研究領域，涵蓋多種瘤種的以MiniPDX為基礎的精準治療方案的對照研究、單臂研究等陸續發表，深化了MiniPDX的循證醫學證據；此外，針對腫瘤精準治療的其它領域/腫瘤類型，我們也期待進一步和各位專家進行合作。
基礎研究領域，以PDX為代表的“金標準”藥效研究手段在腫瘤研究領域受到了廣泛的關注和應用，成為高水平成果轉化的必要工具。MiniPDX由于其與PDX的一致性高，時間和價格上的優勢，具備了部分替代PDX在基礎科研的應用潛力，也得到越來越多專家的青睞。

學術成果匯總：

1.Xu Y, et al. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. Cancer Commun (Lond). 2018 May 9;38(1):19.

2.Zhan M, et al. Guided chemotherapy based on patient?derived mini?xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun (Lond). 2018 Jul 17;38(1):48.

3.Zhang F, et al. Characterization of drug responses of mini patient?derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun (Lond). 2018 Sep 26;38(1):60.

4.Zhao P, et al. Personalized treatment based on mini patient?derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. Cancer Commun (Lond). 2018 Aug 23;38(1):54.

5.Xu et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. 2019 Dec 2;10(1):5492.

6.Li C, et al. Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell. 2020 Nov 9;38(5):734-747.e9.

7.Yang L, et al. MiniPDX?guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma. Cancer Chemother Pharmacol. 2021 Jan;87(1):125-134.

8.Huang Y, et al. A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report. Cancer Manag Res. 2021 Mar 29;13:2849-2867.

9.Wang J, et al. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Lett. 2021 Apr 10;503:197-212.

10.Wang X, et al. Mini-Patient-derived Xenograft Model Based on Microfluidic Technology Promises to be an Effective Tool for Screening Individualized Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer. Cell Biol Int. 2021 Sep;45(9):1887-1896.

11.Zhang X, et al. Stereotactic body radiotherapy-induced abscopal effect twice after pembrolizumab failure in hereditary leiomyomatosis and renal cell carcinoma: a case report with genetic and immunologic analysis. Transl Androl Urol. 2021 Nov;10(11):4304-4312.

12.Ge Y, et al. OncoVee?-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis. Front Oncol. 2022 Jan 3;11:757383.

13.Liu S, et al. Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. Int J Med Sci. 2022 Jan 4;19(2):286-298.

14.Wang J, et al. Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model. J Oncol. 2022 Jan 27;2022:1987705.

15.Chen Y, et al. Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis. Nat Commun. 2022 Feb 10;13(1):791.

16.Xiao Y, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022 May;32(5):477-490.

17.Xu J, et al. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. Cancer Chemother Pharmacol. 2022 May;89(5):683-695.

18.Zhu D, et al. Tubulin-binding peptide RR-171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF-kappa B pathway. Cell Prolif. 2022 May;55(5):e13241.

19.Wang B, et al. miR-638 Serves as a Biomarker of 5-Fluorouracil Sensitivity to Neoadjuvant Chemotherapy in Breast Cancer. J Breast Cancer. 2022 Jun;25(3):193-206.

20.Zhu X, et al. The drugs screened by OncoVeeTM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer. J Oncol Pharm Pract. 2022 Sep;28(6):1435-1440.

21.Zhu X, et al. Individualized therapy based on the combination of mini-PDX and NGS for a patient with metastatic AFP-producing and HER-2 amplified gastric cancer. Oncol Lett. 2022 Sep 27;24(5):411.

22.Li Z, et al. TreeQNet: a webserver for Treatment evaluation with Quantified Network. BMC Bioinformatics. 2022 Nov 11;23(1):473.

23. Long Z, et al. Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study. J Cancer Res Ther. 2023 Feb;19(1):71-77.

24. He J, et al. Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. BMC Neurol. 2023 Mar 4;23(1):96.

25. Zhang B, et al. OncoVee?-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study. Discov Oncol. 2023 Apr 24;14(1):46.

26. Li X, et al. Integrated proteomic and phosphoproteomic data-independent acquisition data evaluate the personalized drug responses of primary and metastatic tumors in colorectal cancer. Biophys Rep. 2023 Apr 30;9(2):67-81.

27. Wang Y, et al. Polyphyllin D punctures hypertrophic lysosomes to reverse drug resistance of hepatocellular carcinoma by targeting acid sphingomyelinase. Mol Ther. 2023 Jul 5;31(7):2169-2187.

28. Yang L, et al. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer. Cell Oncol (Dordr). 2023 Aug;46(4):1085-1095.

29. Yu P, et al. TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Sci Adv. 2023 Sep;9(35):eadg7125.

30. Chen L, et al. Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects. JCI Insight. 2023 Nov 22;8(22):e172366.

31. Huang L, et al. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study. Clin Transl Med. 2023 Dec;13(12):e1500.

32. Hu H, et al. Individualized chemotherapy and efficacy analysis of hepatoblastoma in children. Pediatr Blood Cancer. 2024 Jan;71(1):e30693.

33. Ma J, et al. MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation. Nat Commun. 2024 Feb 29;15(1):1871.

34. Lin C, et al. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer. Cancer Cell. 2024 Apr 8;42(4):701-719.e12.

35. Cui Y, et al. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment. J Cell Mol Med. 2024 May;28(9):e18374.

36. Xu S, et al. Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. EBioMedicine. 2024 Jun:104:105162.

37.Gao Y, et al. Immunotherapy combined with targeted therapy in advanced small cell carcinoma of the ovary of hypercalcemic type: A case of overall survival lasting for over 5 years. Eur J Obstet Gynecol Reprod Biol. 2024 Jun:297:270-274.

38. Rossetti S, et al. Gedatolisib shows superior potency and efficacy versus single - node PI3K/AKT/mTOR inhibitors in breast cancer models. NPJ Breast Cancer. 2024 Jun 5;10(1):40.

39. Li K, et al. The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer. Bone Res. 2024 Aug 27;12(1):47.

40. Jiang M, et al. Patient-derived organoids and mini-PDX for predicting METN375S-mutated lung cancer patient clinical therapeutic response. Heliyon. 2024 Sep 12;10(18):e37884.

41. Tu R, et al. USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression. Cell Death Dis. 2024 Oct 15;15(10):749.

42. Wang B, et al. SNHG14 promotes triple - negative breast cancer cell proliferation, invasion, and chemoresistance by regulating the ERK/MAPK signaling pathway. IUBMB Life. 2024 Dec;76(12):1295-1308.

43. Xu W, et al. Gastric cancer patient with MET amplification treated with crizotinib achieves long-term survival: a case report. AME Case Rep. 2024 Dec 4:9:27.

44. Ma Z, et al. Curculigoside exhibits multiple therapeutic ef?cacy to induce apoptosis and ferroptosis in osteosarcoma via modulation of ROS and tumor microenvironment. Tissue Cell. 2025 Apr:93:102745.

45. Xu R, et al. HLA-F regulates the proliferation of trophoblast via PKM2-dependent glycolysis in the pathogenesis of preeclampsia. Mol Med. 2025 Apr 18;31(1):142.

46. Guo Z, et al. Tertiary lymphoid structures signature predicts prognosis and clinical benefits from neoadjuvant chemotherapy and PD-1 blockade in colorectal adenocarcinoma. Int J Surg. 2025 Aug 1;111(8):5088-5104.

47. Wang Y, et al. Regulatory mechanisms of the Hippo/YAP axis by G-protein coupled estrogen receptor in gastric signet-ring cell carcinoma. Neoplasia. 2025 Sep:67:101199.

48. Xie Y, et al. Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia. J Adv Res. 2025 Oct 27:S2090-1232(25)00856-2.

49. Liu C, et al. Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. Protein Cell. 2025 Nov 4:pwaf091.

50. Wang H, et al. Small nucleolar RNA host gene 1 (SNHG1) facilitates gemcitabine chemosensitivity in gallbladder cancer by regulating the miR-23b-3p/phosphatase and tensin homolog (PTEN) pathway. Chin Med J (Engl). 2025 Nov 5;138(21):2783-2792.

51. Zhang Y, et al. Metachronous Presentation of BCL2-Positive Lung Adenocarcinoma and Acute Myeloid Leukemia: a case presentation and review of the literature. Case Rep Oncol. 2025 Dec 11.

52.張菲菲,等. 用于預測癌癥患者臨床治療方案的小鼠mini人源腫瘤異種移植模型的建立. 癌癥. 2019; 4:165-176.

53.陳漪雯,等. OncoVee MiniPDX (TM)模型指導驅動基因陰性的晚期非小細胞肺癌患者化療的療效分析.實用癌癥雜志. 2019; 8:1325-1327.

54.賈麟,等. MiniPDX模型在晚期肺癌伴惡性胸腔積液患者治療中的指導作用. 中國醫藥導報. 2020;17(20): 131-134.

55.廖海燕,等. 間接體內Mini人源腫瘤異種移植模型再現轉移性腸癌患者的藥物治療療效. 腫瘤綜合治療電子雜志. 2020; 6 (3): 96-102.

56. 周箴,等. 人源化免疫肺癌小鼠模型的建立及其在程序性死亡受體1抑制劑療效評估中的作用. 上海交通大學學報(醫學版). 2020,40(01): 37-43.

57. 聞丹憶,等. 人源性腫瘤組織異種移植模型的應用研究新進展. 藥學進展. 2017,41(05): 381-391.

應用實例

MiniPDX指導的術后用藥方案可顯著延長肝細胞癌患者的生存

近日，天津市第一中心醫院張雅敏教授團隊在權威雜志Cancer Chemotherapy and Pharmacology發表了題為《MiniPDX?guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma》最新的研究論文。該文章顯示，利用MiniPDX模型藥敏檢測指導肝細胞癌患者肝部分切除術后的抗腫瘤用藥可顯著延長患者的生存期。患者中位總生存期從23.8個月延長至29.4個月；中位無病生存期從18.2個月延長至25.8個月。

圖片.png

該研究入組了28例HCC患者，利用其腫瘤組織進行迷你人源性腫瘤移植動物模型（Mini patient derivedxenograft, MiniPDX模型）的建立，并分別測試了肝部分切除術后5組不同的預防用藥方案 (5-FU+奧沙利鉑、吉西他濱、樂伐替尼、瑞戈非尼、索拉非尼)作用下腫瘤細胞的增殖率，以篩選出患者最為敏感的藥物方案。

研究者同時選擇接受經驗性用藥方案索拉非尼進行治療的42例HCC患者作為對照組；分析兩組患者的無病生存期 (DFS)和總生存期 (OS)；同時分析了藥物敏感性與HCC有關的生物標志物（包括AFP, Ki-67, VEGFR, FGFR, P53,和Nrf2）的相關性。

圖片.png

結果顯示，最長隨訪36個月，使用MiniPDX篩選的用藥方案進行治療，HCC患者中位OS為29.4個月，明顯長于使用傳統用藥方案患者的23.8個月 (P=0.039)。而使用MiniPDX用藥方案的患者的中位DFS為25.8個月，同樣明顯長于使用傳統用藥方案的患者的18.2個月 (p=0.022)。

圖片.png

此外，研究人員還發現，不同藥物敏感性與HCC生物標志物之間顯示了一定的相關性：索拉菲尼和樂伐替尼在VEGFR高表達的患者中顯示了更高的抗腫瘤活性；FGFR高表達的HCC患者對瑞戈非尼和樂伐替尼更加敏感；而P53高突變的患者一定程度表現出對細胞毒藥物的耐受；Nfr2低表達的HCC患者中，5-FU聯合奧沙利鉑顯示了更強的細胞毒性。

圖片.png